Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021

Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021

This review discusses reasons for prolonged use of anticoagulants after discharge of patients with COVID-19 without additional indication for anticoagulation. Data regarding rate of thrombotic and thromboembolic complications in patients with COVID-19 after discharge from the hospital are presented....

Full description

Bibliographic Details
Main Author: I. S. Yavelov
Format: Article
Language:English
Published: Столичная издательская компания 2022-01-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
covid-19
venous thromboembolism
deep vein thrombosis
pulmonary embolism
prevention
heparin
enoxaparin
direct oral anticoagulants
rivaroxaban
apixaban
betrixaban
Online Access:https://www.rpcardio.online/jour/article/view/2620

Internet

https://www.rpcardio.online/jour/article/view/2620

Similar Items